KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Novartis Ag (NVS) Shareholder's Equity (2015 - 2025)

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Shareholder's Equity (Qtr)
1	Novartis Ag	107,124,802.25 Bn	107,124,802.25 Bn	-	-
2	Eli Lilly	969.00 Bn	963.72 Bn	16.22 Bn	31.20 Bn
3	Johnson & Johnson	539.46 Bn	517.41 Bn	15.96 Bn	81.19 Bn
4	AbbVie	376.92 Bn	367.57 Bn	10.78 Bn	-6.66 Bn
5	Merck	285.00 Bn	279.35 Bn	12.09 Bn	45.88 Bn
6	Amgen	177.58 Bn	165.55 Bn	5.87 Bn	9.19 Bn
7	Gilead Sciences	163.22 Bn	155.50 Bn	5.52 Bn	23.52 Bn
8	Pfizer	145.86 Bn	133.09 Bn	-1.21 Bn	90.10 Bn
9	Bristol Myers Squibb	111.90 Bn	101.44 Bn	8.07 Bn	20.07 Bn
10	Gsk	88.34 Bn	83.66 Bn	-	21.78 Bn

Historic Data

Download Data 🔒

Date	Value
Dec 31, 2025	46.13 Bn
Dec 31, 2024	44.13 Bn
Dec 31, 2023	46.75 Bn
Dec 31, 2022	59.42 Bn
Dec 31, 2021	67.82 Bn
Dec 31, 2020	-1.42 Bn
Dec 31, 2019	-4.66 Bn
Dec 31, 2018	-69.00 Mn
Dec 31, 2017	59.00 Mn
Dec 31, 2016	74.89 Bn
Dec 31, 2015	77.12 Bn